Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Core Points - Mainz Biomed N.V. has successfully closed a follow-on offering of 1,367,521 units, generating approximately $8.0 million in gross proceeds [1] - Each unit was sold at an effective price of$5.85, which includes one ordinary share and two types of warrants [1] - The Class A and Class B warrants are both immediately exercisable at the same price and have different expiration conditions [1] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, focusing on early cancer detection [3] - The flagship product, ColoAlert®, is a non-invasive test for colorectal cancer, currently marketed in Europe [3] - The company is conducting a pivotal FDA clinical study for regulatory approval in the U.S. and is developing PancAlert, a pancreatic cancer screening test [3]